Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BTK inhibitors
Biotech
Sanofi nails phase 3 LUNA landing, sparking race to regulators
Sanofi plans to file for approval of a “multi-indication blockbuster” that it predicts could contribute to more than 10 billion euros of launch sales.
Nick Paul Taylor
Apr 23, 2024 2:23am
Novartis lines up another potential indication for BTK inhibitor
Mar 9, 2024 12:00pm
Merck KGaA drops evobrutinib in wake of double phase 3 fail
Mar 7, 2024 9:54am
Sanofi BTK inhibitor readout in chronic hives sets up ph. 3 push
Feb 26, 2024 10:35am
Sanofi-backed Sudo seals $116M series B
Dec 20, 2023 8:30am
Merck KGaA's BTK drug flunks pivotal multiple sclerosis trials
Dec 6, 2023 4:30am